EMRUXIV Trademark

Trademark Overview

On Friday, May 20, 2022, a trademark application was filed for EMRUXIV with the United States Patent and Trademark Office. The USPTO has given the EMRUXIV trademark a serial number of 97421223. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Friday, July 26, 2024. This trademark is owned by Principia Biopharma Inc.. The EMRUXIV trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of multiple sclerosis
emruxiv

General Information

Serial Number97421223
Word MarkEMRUXIV
Filing DateFriday, May 20, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateFriday, July 26, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 24, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of multiple sclerosis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 26, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePrincipia Biopharma Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBridgewater, NJ 08807
Party NamePrincipia Biopharma Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBridgewater, NJ 08807

Trademark Events

Event DateEvent Description
Monday, July 11, 2022TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, May 24, 2022NEW APPLICATION ENTERED
Thursday, May 26, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 3, 2022ASSIGNED TO LIE
Wednesday, August 3, 2022PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Thursday, December 22, 2022ASSIGNED TO EXAMINER
Thursday, December 22, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 24, 2023PUBLISHED FOR OPPOSITION
Wednesday, January 4, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 21, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 24, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, August 24, 2023SOU EXTENSION 1 GRANTED
Thursday, August 24, 2023SOU TEAS EXTENSION RECEIVED
Thursday, August 24, 2023SOU EXTENSION 1 FILED
Wednesday, January 31, 2024SOU TEAS EXTENSION RECEIVED
Saturday, August 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 31, 2024SOU EXTENSION 2 FILED
Wednesday, January 31, 2024SOU EXTENSION 2 GRANTED
Friday, July 26, 2024SOU TEAS EXTENSION RECEIVED
Friday, July 26, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 26, 2024SOU EXTENSION 3 GRANTED
Friday, July 26, 2024SOU EXTENSION 3 FILED
Friday, February 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

emruxiv sclerosis multiple treatment preparations pharmaceutical